382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Nancy U. Lin, Virginia F. Borges, Manish R. Patel, Meena Okera, Jane Meisel, Robert Wesolowski, Timothy Pluard, Kathy D. Miller, Nicole McCarthy, Alison Conlin,

Annals of Oncology

Endocrine OncologyBreast OncologyPhase I/ii StudyMedicineHormonal ReceptorPharmacologyAromatasePharmacotherapyBreast CancerSelective Er DegraderCancer TreatmentOncologyRadiation OncologyEndocrine-related CancerHer2-negative Breast Cancer